Ardelyx resubmitted its FDA market application for Xphozah in April, with a decision expected by Oct. 17. If approved, the company said it expects to be able to launch the drug in Q4.
Cantor raised its price target for the stock to $10 from $5.
Ardelyx resubmitted its FDA market application for Xphozah in April, with a decision expected by Oct. 17. If approved, the company said it expects to be able to launch the drug in Q4.
Cantor raised its price target for the stock to $10 from $5.
•
Ardx 目前不錯,在10月份FDA批準之前會漲一波,我前幾天買@4.25
-三絲-
♂
(0 bytes)
()
09/01/2023 postreply
12:27:14